Mangoceuticals Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company was founded on October 7, 2021 and is headquartered in Dallas, TX.

Dallas, Texas, May 02, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies, today announced that the Company received written notification from the Listing Qualification Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company now has until October 24, 2024 to meet the requirement. On the same date, Nasdaq provided notice to the Company that based on the Company's April 25, 2024, Current Report on Form 8-K filing, Nasdaq has determined that the Company complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) which requires companies listed on the Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000. However, Nasdaq also advised that if the Company fails to evidence compliance with the Rule upon filing its next periodic report it may be subject to delisting.

Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Signifies the first major step towards the application process for the certification of its Mango ED oral dissolvable products by Mexico's health governing agency, COFEPRIS

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

The Dallas Based, Direct-to-Consumer Telemedicine Company Brings the FDA-Approved Oral Testosterone Replacement Therapy Treatment to the Telehealth Market

MangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment

Newly developed clinic prescribing system will allow Doctors to prescribe MangoRx products from within practices and clinics

MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth

MangoRx Wants to Keep Fumbles on the Field, Not in the Bedroom, Offering the Losing Team Free MangoRx ED Products for One Year

MANGORX TO OFFER THE BIG GAME'S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE

The Dallas Based, Direct-to-Consumer Telemedicine Company to Offer 2 Months of Free ‘PRIME' by MangoRx, Powered by Kyzatrex®️ (a $498 value) for First 1,000 Subscribers

MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

"King of the Internet" Dave Portnoy's Uber-Popular Sports Media Company to Spotlight FDA-Approved Oral Testosterone Replacement ‘Prime' by MangoRx, Powered by Kyzatrex®

MangoRx's Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11

Dallas, Texas, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (“GROW”) and erectile dysfunction (“ED”) drug (“Mango”), today priced its previously announced underwritten public offering of 4,000,000 shares of its common stock, par value $0.0001 per share, at a public offering price of $0.30 per share, for aggregate gross proceeds of $1,200,000 to the Company, prior to deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price of $0.30 per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering

Mangoceuticals (NASDAQ: MGRX ) stock is dropping on Friday after the men's wellness products company launched a stock offering this morning. That stock offering has the company selling 5 million shares of MGRX stock.

Why Is Mangoceuticals (MGRX) Stock Down 33% Today?

The Dallas Based, Direct-to-Consumer Telemedicine Company Secures Marketing Agreement with Marius Pharmaceuticals Bringing KYZATREX to the Telehealth Market as ‘Prime' by MangoRx

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

Tapping into a market of more than 40,000 pharmacies, retail outlets, and convenience stores across Mexico in 2024 and fueling International Sales Access Across Latin America

Mangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin America

TRYBE Labs to provide MangoRx customers with turnkey at-home blood collection services and solutions Dallas, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product branded ‘GROW' and erectile dysfunction (ED) drug branded “Mango,” today announced that it has selected TRYBE Labs to provide its customers with a minimally invasive FDA approved at-home blood collection device and testing services as the Company seeks to further expand its product lines requiring blood tests and results reviewed by physicians. Using innovative, FDA approved at-home blood collection technology, TRYBE Labs is a CLIA certified and Joint Commission accredited laboratory that provides a direct-to-consumer product which includes an easy-to-use collection kit, full range of testing, and physician-read results for male health and performance evaluation - including hormone, thyroid and vitamin levels.

Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider

DALLAS, TX / ACCESSWIRE / November 16, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," today announced the expansion of its men's health product line with the addition of its hair growth treatment, ‘ Grow .' The custom compounded hair growth treatment combines four clinically proven hair growth products - Minoxidil, Finasteride, Vitamin D3, and Biotin - encapsulated in convenient chewable, mint-flavored tablets.

Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx

Dallas, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” announces that it will donate a percentage of proceeds generated through the sale of its branded merchandise to select men's health and wellness charities throughout the month of November.

Mangoceuticals, Inc. Launches Charitable Initiative in Support of Men's Health Awareness Month

Announcement follows launch of Affiliate Program to Drive Further Awareness and Growth Dallas, Texas, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is excited to announce the official launch of the Company's new TikTok and Instagram Social Media Influencer Initiative, featuring top relevant influencers with vast global fan bases on the world's leading social media platforms. After initial traction, the Company is ramping up its exposure by working to deepen its connection with the wildly popular Barstool Sports brand and Glenny Balls, famous American Podcaster, Blogger, TV personality, and Influencer on the Barstool Sports team as a top influencer.

Mangoceuticals Launches TikTok Influencer Initiative and Becomes the Presenting Sponsor of the Only Stans Podcast with Glenny Balls

Dallas, Texas, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to announce that the Company's CEO, Jacob Cohen, will join Anna Berry on FMW Media's “New To The Street” business TV show featuring an in-depth interview this weekend.

Mangoceuticals Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Bloomberg TV and Fox Business

Dallas, Texas, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is excited to announce the official launch of its affiliate marketing program via its newly designed website at www.MangoRevenue.com.

Mangoceuticals Announces the Official Launch of MangoRx Affiliate Marketing Program to Enhance and Accelerate Topline Growth

Dallas, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is excited to announce the official launch of its new high-production-quality commercial that provides more insight into the Company's proprietary mango-flavored ED formula, which now comes in both sildenafil and tadalafil forms.

Mangoceuticals Launches New High-Production Quality Ad Providing Fresh Insight into its Proprietary Mango Erectile Dysfunction Pill Formula

Dallas, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” today announced the official commercial launch of its second Mango ED product, which leverages the Company's existing custom compound alongside Sildenafil, the active ingredient found in Viagra™.

Mangoceuticals Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve

Dallas, Texas, July 18, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is excited to announce that it has been engaged as an exclusive new sponsor by Adam22 and will be featured on a series of No Jumper and Plug Talk episodes beginning in August 2023 (https://www.youtube.com/@NoJumper).

Mangoceuticals Engaged by Social Media Sensation Adam22 as Exclusive New Sponsor of Hit Podcasts with Skyrocketing Male Engagement

DALLAS, TX / ACCESSWIRE / June 29, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded "Mango," is excited to announce its new collaboration with Ice Shaker to supply custom-made Mango-branded Ice Shaker bottles to be sold exclusively on the company's new MakeAmericaHardAgain.com e-commerce portal. Ice Shaker was founded by former NFL player, Chris Gronkowski in 2016 with a vision and mission to become a premium alternative to traditional, plastic shaker bottles.

Mangoceuticals Collaborates with Ice Shaker to Launch Mango Branded Ice Shaker Protein Bottles on MakeAmericaHardAgain.com

Dallas, Texas, June 27, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to announce the launch of its new “Make America Hard Again” nationwide marketing campaign and website, www.MakeAmericaHardAgain.com.

Mangoceuticals Launches “Make America Hard Again” Campaign & Merchandise Website

Dallas, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling multiple men's health and wellness products through a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug, “Mango,”, is pleased to announce the upcoming release of its second Mango ED product leveraging the Company's existing custom compound alongside Sildenafil, which is the active ingredient found in Viagra™.

Mangoceuticals, Inc. Announces Upcoming Launch of its Sildenafil Based Mango Flavored Rapid Dissolve ED Product

Mangoceuticals continues to increase its marketing of Mango & corporate visibility, jointing many well-known podcasts in the epicenter of uncensored and unfiltered comedy

Mangoceuticals, Inc. Signs Sponsorship Agreement with GaS Digital Network to Promote Mango Across Multiple Hardcore Comedy Podcasts

Shares of Mangoceuticals Inc. MGRX, +10.81% fell 6.7% in premarket trading, to extend their sharp pullback from the previous session's intraday high. The stock had rocketed as much as 60.8% to an intraday high of $2.38 soon after Thursday's open, but closed up just 10.8%, after the erectile dysfunction (ED) drug maker announced a sponsorship deal with Barstool Sports.

News for Mangoceuticals Inc Stock (MGRX)